ResearcherKitano HospitalActive in the last 2 years
Shujiro Yazumi
Matched on ORCID iD 0000-0002-0683-0000; OpenAlex author ID A5004009208. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 51
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers
Papers 11
- Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Co-author DOI 10.1097/mpa.0000000000002710↗
- Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Cancer. Co-author DOI 10.3390/cancers18071177↗
- Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. Co-author DOI 10.1038/s41416-024-02794-5↗
- High signal intensity on diffusion-weighted magnetic resonance images is a useful finding for detecting early-stage pancreatic cancer. Last author DOI 10.1007/s00261-021-03199-1↗
- Metastasis of Pancreatic Cancer to Cerebellum Resembles Meningitis. Last author DOI 10.1016/j.cgh.2020.04.082↗
- Usefulness of immunohistochemical staining for MUC5AC in differentiating primary pancreatic cancer from pancreatic metastasis of breast cancer. Last author DOI 10.1002/dc.24249↗
- Paraplegia as an initial manifestation of pancreatic cancer. Last author DOI 10.1002/jgh3.12194↗
- [A screening strategy for detecting early pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.115.338↗
- Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-015-0864-x↗
- Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis … Co-author DOI 10.1016/j.ejca.2015.11.002↗
- A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1007/s00280-010-1470-2↗
Closest collaborators
The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Akira Kurita · 6 shared papers, 2016–2026 · strength 0.87
- Paper Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicente… DOI 10.1097/mpa.0000000000002710↗
- Paper Metastasis of Pancreatic Cancer to Cerebellum Resembles Meningitis. DOI 10.1016/j.cgh.2020.04.082↗
- Paper [A screening strategy for detecting early pancreatic cancer]. DOI 10.11405/nisshoshi.115.338↗
- Hiroshi Seno · 3 shared papers, 2019–2026 · strength 0.48
- Paper Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Can… DOI 10.3390/cancers18071177↗
- Paper Paraplegia as an initial manifestation of pancreatic cancer. DOI 10.1002/jgh3.12194↗
- Paper Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. DOI 10.1038/s41416-024-02794-5↗
- Akihisa Fukuda · 3 shared papers, 2019–2026 · strength 0.48
- Paper Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Can… DOI 10.3390/cancers18071177↗
- Paper Paraplegia as an initial manifestation of pancreatic cancer. DOI 10.1002/jgh3.12194↗
- Paper Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. DOI 10.1038/s41416-024-02794-5↗
- Kei Iimori · 2 shared papers, 2021–2026 · strength 0.43
- Kosuke Minaga · 2 shared papers, 2024–2026 · strength 0.34
- Paper Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Can… DOI 10.3390/cancers18071177↗
- Paper Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. DOI 10.1038/s41416-024-02794-5↗
- Munenori Kawai · 2 shared papers, 2024–2026 · strength 0.34
- Paper Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Can… DOI 10.3390/cancers18071177↗
- Paper Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. DOI 10.1038/s41416-024-02794-5↗
- Toshihiro Morita · 2 shared papers, 2024–2026 · strength 0.34
- Paper Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Can… DOI 10.3390/cancers18071177↗
- Paper Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. DOI 10.1038/s41416-024-02794-5↗
- Atsushi Umemura · 2 shared papers, 2024–2026 · strength 0.34
- Paper Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Can… DOI 10.3390/cancers18071177↗
- Paper Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. DOI 10.1038/s41416-024-02794-5↗
- Masao Tanaka · 2 shared papers, 2016–2026 · strength 0.28
- Paper Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicente… DOI 10.1097/mpa.0000000000002710↗
- Paper Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, … DOI 10.1016/j.ejca.2015.11.002↗
- Makoto Sono · 2 shared papers, 2019–2024 · strength 0.27
- Atsushi Kanno · 1 shared paper, 2026 · strength 0.22
- Mamoru Takenaka · 1 shared paper, 2026 · strength 0.22
- Yukiko Takayama · 1 shared paper, 2026 · strength 0.22
- Reiko Ashida · 1 shared paper, 2026 · strength 0.22
- Yasutaka Ishii · 1 shared paper, 2026 · strength 0.22
- Noboru Ideno · 1 shared paper, 2026 · strength 0.22
- Takao Ohtsuka · 1 shared paper, 2026 · strength 0.22
- Keiji Hanada · 1 shared paper, 2026 · strength 0.22
- Akio Yanagisawa · 1 shared paper, 2026 · strength 0.22
- Akinori Shimizu · 1 shared paper, 2026 · strength 0.22
- Koji Yoshida · 1 shared paper, 2026 · strength 0.22
- Toru Furukawa · 1 shared paper, 2026 · strength 0.22
- Masayuki Kitano · 1 shared paper, 2026 · strength 0.22
- Kazuyuki Nagai · 1 shared paper, 2026 · strength 0.21
- Etsuro Hatano · 1 shared paper, 2026 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.